Starpharma Holdings Limited SPL.AX · Stock Open Starpharma Holdings Limited in new tab
Starpharma Holdings Limited Analysis (SPL.AX)
Is Starpharma Holdings Limited a good investment? Starpharma Holdings Limited (SPL.AX) is currently trading at 0.8000 AUD.
Earnings Schedule: Starpharma Holdings Limited is expected to release its next earnings report on March 2, 2027.
Investor FAQ
Does Starpharma Holdings Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is Starpharma Holdings Limited?
Starpharma Holdings Limited is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be March 2, 2027.
Company Profile
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Community Discussion